BRIEF-Xeris Biopharma Reports Q3 2024 Financial Results

Reuters11-08

Nov 8 (Reuters) - Xeris Biopharma Holdings Inc :

* XERIS BIOPHARMA REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS

* XERIS BIOPHARMA HOLDINGS: RAISES FY GUIDANCE OF TOTAL NET REVENUE TO $198 MILLION - $202MLN & TIGHTENS YEAR-END CASH TO $68MLN - $72MLN

* XERIS BIOPHARMA HOLDINGS: CASH, CASH EQUIVALENTS, & SHORT-TERM INVESTMENTS AT SEPT 30, 2024 WAS $69.4 MILLION

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481171536?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 20:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481171536","market":"us","top_or_hot":-1,"title":"BRIEF-Xeris Biopharma Reports Q3 2024 Financial Results","media":"Reuters","content":"<html><body><p>Nov 8 (Reuters) - Xeris Biopharma Holdings Inc   :</p><p>   * XERIS BIOPHARMA REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS</p><p>   * XERIS BIOPHARMA HOLDINGS: RAISES FY GUIDANCE OF TOTAL NET REVENUE TO $198 MILLION - $202MLN &amp; TIGHTENS YEAR-END CASH TO $68MLN - $72MLN</p><p>   * XERIS BIOPHARMA HOLDINGS: CASH, CASH EQUIVALENTS, &amp; SHORT-TERM INVESTMENTS AT SEPT 30, 2024 WAS $69.4 MILLION</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Xeris Biopharma Reports Q3 2024 Financial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Xeris Biopharma Reports Q3 2024 Financial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 20:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 8 (Reuters) - Xeris Biopharma Holdings Inc   :   * XERIS BIOPHARMA REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS   * XERIS BIOPHARMA HOLDINGS: RAISES FY GUIDANCE OF TOTAL NET REVENUE TO $198 ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2481171536","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481171536","pubTimestamp":1731068817,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Nov 8  - Xeris Biopharma Holdings Inc   :   * XERIS BIOPHARMA REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS   * XERIS BIOPHARMA HOLDINGS: RAISES FY GUIDANCE OF TOTAL NET REVENUE TO $198 MILLION - $202MLN & TIGHTENS YEAR-END CASH TO $68MLN - $72MLN   * XERIS BIOPHARMA HOLDINGS: CASH, CASH EQUIVALENTS, & SHORT-TERM INVESTMENTS AT SEPT 30, 2024 WAS $69.4 MILLIONSource text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","XERS":"Xeris制药"},"translate_title":"简介-Xeris Biopharma报告2024年第三季度财务业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XERS":0.9},"content_text":"Nov 8 (Reuters) - Xeris Biopharma Holdings Inc   :   * XERIS BIOPHARMA REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS   * XERIS BIOPHARMA HOLDINGS: RAISES FY GUIDANCE OF TOTAL NET REVENUE TO $198 MILLION - $202MLN & TIGHTENS YEAR-END CASH TO $68MLN - $72MLN   * XERIS BIOPHARMA HOLDINGS: CASH, CASH EQUIVALENTS, & SHORT-TERM INVESTMENTS AT SEPT 30, 2024 WAS $69.4 MILLIONSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481171536"}